Everyone is talking about BPC-157. Almost no one has measured it in a person.

2026-09-16

The quick version

BPC-157 is a peptide that a lot of people are talking about.

When FDA reviewed it in 2026, it found no data on what happens to it inside a person's body by any of the usual routes.

That is not proof it does nothing. It means the measurements in people have not been made.

How do we know people are using it?

By the mid-2010s, an anti-doping lab needed a way to test for it in vials taken from athletes. In June 2023, FDA sent a warning letter to a firm selling it as an injectable and a nasal spray. And the US Anti-Doping Agency says it is banned in sport.

Nobody writes papers like these about something no one is buying. This post is about the other side. What has actually been measured when BPC-157 goes into a person?

FDA took a close look

Two groups had asked FDA to add BPC-157 to a list. It's the list of ingredients pharmacies are allowed to use in custom-mixed medicines. Its official name is the 503A Bulks List.

So in 2026, FDA had to review it. The review is public. It's the most thorough attempt anyone has made to gather what is known about BPC-157 in one place.

What FDA found in people

Scientists call what the body does with a substance its pharmacokinetics. That's different from what the substance is said to do to the body.

FDA looked for this kind of data in people. It found none. Not a little. Not mixed results. None, for BPC-157 taken by mouth, under the skin, in the nose or on the skin.

Only two published studies gave it to people more than once. Both gave it as an enema. In both, the authors report they couldn't find it in people's blood. One, published only as a short abstract, says most blood levels were too low for the test to measure.

Each count is a human study FDA found, in its 503A Bulks List review, of what happens to BPC-157 in the body. Hollow dots sit at zero. The filled dot sits at two. The empty rows mean FDA found no data for those routes. They do not mean studies were done and came back negative.

Table view

Route	Human PK studies FDA identified	Reported result
Oral	0	No data identified
Subcutaneous	0	No data identified
Nasal	0	No data identified
Transdermal	0	No data identified
Rectal (enema)	2	Not detected in plasma samples; in one abstract most concentrations below the assay's lower limit of quantification

"Couldn't find it" is about the test

"Not detected" tells you about the test, not the molecule. A substance might not show up for several reasons:

Very little of it got into the blood.
The body cleared it before anyone took a sample.
It broke into pieces the test wasn't looking for.
The test wasn't sensitive enough.

The published record doesn't say which.

So the finding is not that BPC-157 was measured in people and came up short. It's that nobody has measured it in people by any route people use. Those are two different claims. Only the second is backed by the evidence.

The numbers you see are from rats and dogs

Most numbers you'll see come from a careful study in rats and dogs.

In both animals, the peptide's half-life was under 30 minutes. That's how long it takes for half to be cleared. When it was given into muscle, about 14 to 19 per cent reached the bloodstream in rats. In dogs, it was about 45 to 51 per cent.

Those are real measurements. But FDA says they can't be stretched to cover other routes. No one knows how much reaches the bloodstream in these animals by mouth, rectally, on the skin, under the skin or in the nose.

The animal safety work has the same gap. For those five routes, FDA found no animal studies of how the body handles it. It also found none on harm from single doses, repeated doses or during development.

The paper trail

The regulatory record is much thicker than the science.

Dates come from FDA's warning letter, its 503A Bulks List review and the advisory committee's materials. The two 2026 dots overlap because they sit ten weeks apart on a ten-year scale.

Table view

Date	Event
Jan 2017 – Jun 2025	FDA outsourcing facility product reporting: no reported compounded drug products containing BPC-157 (free base) or BPC-157 acetate
12 June 2023	FDA warning letter to a firm selling BPC-157 in injectable and nasal spray form; product stated to be an unapproved new drug under section 201(p) of the FD&C Act
11 May 2026	FDA evaluation proposes not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List
23 July 2026	Pharmacy Compounding Advisory Committee takes up both substances; no minutes, transcript or vote record published as of this writing

The warning letter is often misread

In 2023, FDA told that firm its product was "not generally recognized as safe and effective for the above referenced uses and, therefore, [is a] 'new drug[]' under section 201(p) of the FD&C Act".

That finding was about those products, as that firm sold them, with those claims. It was not a ruling about the molecule itself. It still gets cited as if it were.

What did FDA decide in 2026?

On 11 May 2026, FDA wrote: "Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List".

It gave four reasons. Neither form is well described chemically. There's a lack of safety information, including the risk of an immune reaction. The evidence isn't enough to reach a conclusion on effectiveness. And approved drugs already exist for the proposed use.

Ten weeks later, on 23 July 2026, an FDA advisory committee took up both forms. Its advice doesn't bind FDA. As of this writing, no minutes, transcript or vote record has been published.

Where it sits today

BPC-157 is now on an FDA page of substances that may present significant safety risks, in the "nominated but withdrawn" table.

FDA searched and found no approved product with BPC-157 in any country.

A zero that's easy to miss

Some compounding sites register with FDA as outsourcing facilities, and report what they make. From January 2017 to June 2025, they reported no products with either form of BPC-157. None, across eight and a half years.

But as FDA notes, regular compounding pharmacies usually don't report to that database. So this is one window into the supply, not the whole picture.

How many human studies are there?

FDA found five clinical studies of BPC-157 in all the published medical literature. Two are only meeting abstracts. FDA calls the set short, small and limited in safety information.

There is no published, properly reported randomised trial of it in people, for any condition.

An independent review of bone and joint research screened 544 articles and kept 36. Only one was in people. The authors found no clinical safety data.

The studies that report good outcomes can't settle much. One enrolled just 12 women at one clinic, with no comparison group. In another, some people got BPC-157 mixed with a second peptide, so nothing in it can be pinned on BPC-157 alone.

A phase 1 study in healthy volunteers, NCT02637284, began in 2015. Its results were never posted. An independent review records that the researchers cancelled submitting the results in 2016.

One lab, a lot of papers

Hold this one loosely. A STAT news investigation quotes a review team's count. By that count, the vast majority of the roughly 200 BPC-157 studies on PubMed include Predrag Sikiric or Sven Seiwerth as a main author. Both are at the University of Zagreb.

That's a journalist reporting someone else's count. But the first 1993 paper did come from that same department.

So what does it all add up to?

None of this is a verdict on whether BPC-157 does anything in a person. That verdict isn't available.

This isn't a debunk, either. "It doesn't work" is a claim too, and it needs evidence just like the opposite claim. FDA did not report measuring BPC-157 in people and finding it had no effect. It reported that the measurement hasn't been made.

A warning letter. A ban in sport. A full FDA review and an advisory committee meeting. And still no published measurement of what happens to it in a person's bloodstream, by any route a person is likely to use.

The conversation has run a long way ahead of the measurements. That gap is the finding.

Sources

All articles